Ocular Therapeutix (NASDAQ: OCUL) officer to sell $32.7K stock

Rhea-AI Filing Summary

OCULAR THERAPEUTIX, INC. (OCUL) received a Rule 144 notice from officer Peter Kazuo Kaiser covering a planned sale of company common stock. The notice lists 3,035 shares of common stock to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ, with an indicated aggregate value of $32,701.82. The shares relate to restricted stock vesting under a registered plan, with vesting and proposed sale timing noted in August 2026. The filing also reports that over the prior three months, Peter Kazuo Kaiser sold 2,967 shares of OCUL common stock for total proceeds of $24,333.55.

Key Figures

Planned shares to be sold: 3,035 shares Aggregate value of planned sale: $32,701.82 Shares sold in prior 3 months: 2,967 shares +3 more

6 metrics

Planned shares to be sold 3,035 shares Common stock to be sold under Rule 144 by officer Peter Kazuo Kaiser

Aggregate value of planned sale $32,701.82 Total indicated value for 3,035 OCUL common shares in planned Rule 144 sale

Shares sold in prior 3 months 2,967 shares OCUL common stock sold by Peter Kazuo Kaiser on 05/26/2026

Proceeds from prior sale $24,333.55 Total consideration for 2,967 OCUL shares sold on 05/26/2026

Vest date of restricted stock 08/22/2026 Restricted stock vesting date under a registered plan related to the planned sale

Proposed sale timing reference 08/24/2026 Date associated with the proposed sale details for the 3,035 shares

Key Terms

Rule 144, restricted stock, registered plan, Executive Financial Services

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

restricted stock financial

"Restricted Stock Vesting Under a Registered Plan"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

registered plan regulatory

"Restricted Stock Vesting Under a Registered Plan"

A registered plan is a savings or investment account that a government recognizes for special tax treatment and rules, such as limits on how much you can put in and conditions for withdrawals. For investors it matters because those rules change how much of your gains are taxed, how quickly your money can be accessed and what strategies make sense — like a labeled jar that gives tax breaks but comes with rules about when and how you can take the money out.

Executive Financial Services financial

"Morgan Stanley Smith Barney LLC Executive Financial Services"

FAQ

What does the Form 144 filing disclose for OCUL?

It discloses that officer Peter Kazuo Kaiser has filed a notice under Rule 144 to sell 3,035 shares of OCULAR THERAPEUTIX, INC. common stock, with an indicated aggregate value of $32,701.82, to be sold through Morgan Stanley Smith Barney LLC on NASDAQ.

How many OCUL shares are planned for sale under this Form 144?

The notice covers a proposed sale of 3,035 shares of OCULAR THERAPEUTIX, INC. common stock. These shares are linked to restricted stock vesting under a registered plan with vesting and proposed sale timing in August 2026.

What is the aggregate value of the OCUL shares in the planned Rule 144 sale?

The planned Rule 144 sale by Peter Kazuo Kaiser lists an aggregate value of $32,701.82 for the 3,035 OCUL common shares to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services.

Who is selling OCUL shares in this Form 144 and in what capacity?

The seller is Peter Kazuo Kaiser, identified as an officer of OCULAR THERAPEUTIX, INC. The filing is a notice of proposed sales of the company’s common stock under Rule 144.

What OCUL stock sales has Peter Kazuo Kaiser made in the last three months?

Over the past three months, the filing reports that Peter Kazuo Kaiser sold 2,967 shares of OCULAR THERAPEUTIX, INC. common stock on 05/26/2026 for total proceeds of $24,333.55.

Through which broker will the OCUL Rule 144 shares be sold?

The proposed sale of 3,035 OCUL shares under Rule 144 will be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, New York, with the shares listed for trading on NASDAQ.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/24/2026 - 04:43 PM Accepted by SEC EDGAR 08/24/2026 - 04:43 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002011869
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	OCULAR THERAPEUTIX, INC.
SEC File Number	001-36554
Address of Issuer	14 CROSBY DRIVE, 3RD FLOOR BEDFORD MASSACHUSETTS 01730
Phone	781-357-4000
Name of Person for Whose Account the Securities are To Be Sold	PETER KAZUO KAISER
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	3035	32701.82	219615868	08/24/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/22/2026	Restricted Stock Vesting Under a Registered Plan	Issuer			3035	08/22/2026	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
PETER KAZUO KAISER 15 Crosby Drive Bedford MA 01730	Common	05/26/2026	2967	24333.55

144: Remarks and Signature

Remarks
Date of Notice	08/24/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Peter Kazuo Kaiser
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)